Bone marrow stem cell mobilization
This patented treatment method and drug composition promotes the mobilization of bone marrow stem cells by inhibiting the oncostatin M (OSM). It finds use especially in the treatment of diabetic patients or of those affected by poor mobilizer condition, in case of bone marrow transplant or for the purposes of cardiovascular protection.
Diabetes compromises the mobility of stem cells from bone marrow to peripheral blood vessels as a response to tissue ischemia or as a consequence of growth factor administration (G-CSF). Such malfunction, that reduces the stem cells from bone marrow, contributes to tissue damage in diabetic patients, which in turn increases the risk of cardiovascular events, neoplasia, infection and chronic or acute degenerative illness.
This patented drug treatment induces the mobilization of stem cells in diabetic or poor mobilizer patients by inhibiting Oncostatin M or the bond with its receptor. The mechanism is based on the fundamental role of CXCL12/SDF-1α, in alternative to other currently available therapies.
Inhibition of OSM for the mobilization of bone marrow stem cells in:
- Autologus Stem cell transplantation;
- Prevention or treatment of cardiovascular disease;
- Stem cell donators;
- Active ingredient targeting optimization of organs (bone marrow).
- Currently the available treatments for poor mobilizer condition are costly and have a limited effect over time (e.g. CXCR4).